Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC 3Q11 Trend Analysis, now available
    - OnBioVC 4Q11 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • FDA Registered Contract Manufacturer

ZocDoc (New York, NY) a commercial-stage web-based healthcare provider network and appointment service, closed a $25M Series C, bringing the total financing to $75M. Participants inculde Goldman Sachs and DST Global.

Phreesia (New York City, NY) a commercial-stage provider of patient check-in systems, closed a $20M Series D financing. Participants include VantagePoint, Ascension Health Ventures, Polaris Venture Partners, HLM Venture Partners, Long River Ventures and BlueCross BlueShield Venture Partners.

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

Rheonix (Ithaca, NY) a development-stage molecular diagnostic company focused on immunoassays, pathogen identification gene sequence detection and cell-based assays, closed a $12.6M Series A financing. Participants include Cayuga Venture Fund.

Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.

Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.

Therasis (New York, NY) a development-stage computational systems biology cancer HTS drug discovery platform, closed a $12M Series A financing. Participants include Tilocor Life Science.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Paradigm Spine (New York, NY) a clinical-stage medical device company focused on lumbar stabilization and interspinous implants, closed a $6.5M Series E financing. Participants include Praefinium Group and Trevi Health Ventures.

Core Dynamics (Orangeburg, NY) a development-stage company focused on the freezing and lyophilization of white blood cells and stem cells and their preservation and storage at room temperature, closed a $17.9M Series B financing. Participants were not disclosed.

MetaCure (Orangeburg, NY) a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation, closed a $20M Series B financing. Participants include the Morningside Group.

Palyon Medical (New York, NY) a preclinical-stage medical device company focused on a spin-based drug delivery system, closed a $21M Series A financing. Participants include Baird Venture Partners, Hambrecht & Quist, Fountain Healthcare Partners, BB Biotech Ventures, Cross Atlantic Partners and Arcus Ventures.

Phreesia (New York, NY) commercial-stage device product automating patient check-in and wireless interface with physicians’ existing and future technology, closed a $11.6M Series C financing. Participants include BlueCross BlueShield Venture Partners, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

« Previous Entries  

to top of page...